Physician profile
Omar Ahmed
NPI 1831517002
$3,825.90
in general payments reported to CMS, 2019-2025
27 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $211 · 2021: $452 · 2022: $810 · 2023: $588 · 2024: $907 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Travel and Lodging: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.05 |
| Travel and Lodging | $434.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.60 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Intuitive Surgical, INC. | $434.00 | 2024 | |
| Allergan, INC. | $369.13 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $268.38 | 2022-2024 | Ongentys, Ingrezza |
| Teva Pharmaceuticals USA, INC. | $154.34 | 2019-2021 | |
| Lilly USA, LLC | $140.26 | 2019-2024 | Emgality, Amyvid |
| Genzyme Corporation | $137.10 | 2020-2022 | |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2019 | |
| Depuy Synthes Sales INC. | $117.84 | 2023 | Monovisc, Orthovisc |
| Astrazeneca Pharmaceuticals LP | $115.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $111.61 | 2019-2020 | |
| Neuronetics, INC. | $70.52 | 2021 | |
| Pfizer INC. | $56.19 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.35 | 2022-2025 | Uplizna |
| Cequr Corporation | $33.09 | 2024 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $31.10 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $29.53 | 2024 | Crysvita |
| Amneal Pharmaceuticals LLC | $27.87 | 2025 | Crexont |
| Medtronic, INC. | $26.91 | 2025 | Percept PC Brainsense |
| Lundbeck LLC | $25.54 | 2021 | |
| Ucb, INC. | $24.08 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.60 | 2022 | |
| W. L. Gore & Associates, INC. | $20.69 | 2021 | |
| Biogen, INC. | $20.00 | 2021 | |
| Ibsa Pharma INC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.